Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 12 September 2023, 18:05 HKT/SGT
Share:
    

Source: Eisai
Eisai Establishes Theoria Technologies Co., Ltd., A New Digital Business Company To Build A Dementia Ecosystem

TOKYO, Sept 12, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has established a digital business company Theoria technologies Co., Ltd. ("Theoria technologies") which will accelerate the development of a dementia ecosystem. Theoria technologies is a wholly owned subsidiary of Eisai.

With the aim of relieving the anxieties of people with dementia and their families and addressing social issues, Eisai is not only creating therapeutic drugs, but also working to build a dementia ecosystem through the development of digital solutions and collaboration with other industries. Theoria technologies will serve as the core of a highly transparent and neutral dementia platform, and the foundation for the development of an ecosystem to empower the people with dementia, regardless of the type or stage of the disease, to "live their fullest lives".

Theoria technologies will accelerate decision-making and strengthen the hiring and training of digital talent under an organizational structure optimized for digital business, and will utilize clinical study data that Eisai has accumulated over many years as well as cohort study data, Personal Health Records (PHR), and other data to develop various prediction algorithms, create digital solutions and provide data. Theoria technologies will commence business activities in April 2024, with the aim of providing services for a risk prediction algorithm for early detection of mild cognitive impairment (MCI) and dementia in FY2024. In addition, together with Eisai, Theoria technologies will develop and provide Sasaeru, an application that helps facilitate communication between people with dementia, doctors, and caregivers by recording Activities of Daily Living (ADL) of the people with dementia. Furthermore, Theoria technologies will promote the development of digital services by strengthening collaboration with other companies.

Eisai is aiming to create social impact by realizing a Dementia Inclusive Society where people with dementia and the people in the daily living domain can live their lives how they would like, through the development of an ecosystem.

For more information, visit www.eisai.com/news/2023/news202356.html.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Feb 21, 2024 14:26 HKT/SGT
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
Feb 20, 2024 08:35 HKT/SGT
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 16, 2024 08:31 HKT/SGT
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
Feb 1, 2024 17:04 HKT/SGT
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
Jan 26, 2024 15:26 HKT/SGT
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
Jan 18, 2024 14:12 HKT/SGT
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan
Jan 17, 2024 16:08 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time
Jan 16, 2024 09:25 HKT/SGT
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024
Jan 11, 2024 15:33 HKT/SGT
Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU
Jan 10, 2024 09:15 HKT/SGT
"> Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: